<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857192</url>
  </required_header>
  <id_info>
    <org_study_id>SAMSON APJ 2014</org_study_id>
    <nct_id>NCT02857192</nct_id>
  </id_info>
  <brief_title>Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease</brief_title>
  <acronym>ACG et TREG</acronym>
  <official_title>Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Giant Cell Arteritis (Horton's Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Giant cell arteritis (GCA) is the most frequent vascularitis after 50 years of age The&#xD;
      investigators recently showed that GCA was accompanied by an elevation in Th1 and Th17&#xD;
      response [1]. Even though a quantitative deficit in regulatory TL (Treg) was shown, there are&#xD;
      to date no data concerning their precise phenotypic and functional characteristics and&#xD;
      notably their ability to inhibit Th1 and Th17 polarisation. The hypothesis of the&#xD;
      investigator is that, in GCA, there is quantitative and above all functional deficit of Treg.&#xD;
      Recently, progress has been made in the identification of Treg with new markers (CD39), which&#xD;
      will make it possible to better identify and to study their specific functions. In this study&#xD;
      the phenotypic and functional characteristics of Treg in GCA will be analysed. Better&#xD;
      understanding of the role des Treg in GCA should lead to better-targeted treatments for&#xD;
      patients with GCA, notably via the blockage of cytokines that inhibit the differentiation&#xD;
      and/or function of Treg.&#xD;
&#xD;
      The study is classified interventional because a lot of blood samples are taken.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement by flow cytometry of the percentage of CD39+ Treg (CD4+CD25highFoxP3+CD39+) among total CD4 TL</measure>
    <time_frame>through study completion an average of 30 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Horton's Disease</condition>
  <arm_group>
    <arm_group_label>Horton</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Horton</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  Patients who have provided written consent&#xD;
&#xD;
          -  Patients with national health insurance cover&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Patients with a diagnosis of Horton's disease, before any treatment&#xD;
&#xD;
        Horton's disease is defined by the American College Rheumatology ACR criteria [2], as the&#xD;
        association of 3 of the following 5 criteria:&#xD;
&#xD;
          -  age at disease onset 50 years or older&#xD;
&#xD;
          -  recent onset localized headache&#xD;
&#xD;
          -  indurated temporal artery or diminished/abolition of temporal pulse&#xD;
&#xD;
          -  erythrocyte sedimentation rate (ESR) greater than 50 mm during the first hour (or C&#xD;
             Reactive protein (CRP)&gt;20 mg/L)&#xD;
&#xD;
          -  Positive temporal artery biopsy (TAB) showing vascularitis with infiltration by&#xD;
             mononuclear cells or granulomatous inflammation with or without giant cells.&#xD;
&#xD;
        Control subjects&#xD;
&#xD;
        Control subjects will be healthy volunteers recruited among blood donors at Dijon&#xD;
        University Hospital, voluntary hospital personnel (nurses, doctors, laboratory technicians&#xD;
        and secretaries) and patients without infectious, inflammatory or auto-immune diseases or&#xD;
        cancer (CRP&lt;5mg/L) recruited in the investigating departments of Dijon Hospital. They will&#xD;
        be matched for age and sex and must meet the following criteria:&#xD;
&#xD;
          -  Age &gt; 50 years&#xD;
&#xD;
          -  Patients with national health insurance cover&#xD;
&#xD;
          -  Signed written informed consent form&#xD;
&#xD;
          -  Absence of an inflammatory syndrome (CRP&lt;5 mg /L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adult under guardianship&#xD;
&#xD;
          -  Persons without national health insurance cover&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients treated with corticoids or immunosuppressants in the month preceding&#xD;
             inclusion&#xD;
&#xD;
          -  Patients treated with chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>51 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

